Cytokinetics Incorporated (NASDAQ:CYTK) traded at $34.82 at close of the session on Tuesday, 01/11/22, made a downward move of -2.74% on its previous day’s price.
Looking at the stock we see that its previous close was $35.80 and the beta (5Y monthly) reads 1.24 with the day’s price range being $34.26 – $36.02. In terms of its 52-week price range, CYTK has a high of $47.90 and a low of $17.72. The company’s stock has lost about -3.55% over that past 30 days.
3 Tiny Stocks Primed to Explode The world’s greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We’ve set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Cytokinetics Incorporated has a market cap of $3.22 billion and is expected to release its quarterly earnings report on Feb 23, 2022 – Feb 28, 2022. Estimates by analysts give the company expected earnings per share (EPS) of -$0.85, with the EPS growth for the year raised at -$3.32 for 2021 and -$3.49 for next year. These figures represent -68.50% and -5.10% growth in EPS for the two years respectively.
Analysts tracking the company’s growth have also given it a consensus growth in revenue estimated at $7.1 million, with a low of $6.04 million and a high of $8.57 million. The median projection represents growth squeezing down to 5.60% compared to sales growth for the corresponding quarter a year ago. According to analyst consensus estimates figures, the company’s yearly revenue forecast for 2021 is expected to hit $22.66 million, or -59.40% down from figures reported last year.
There have been no upward and no downward revisions for the stock’s EPS in last 7 days, something that reflects the nature of company’s price movement in short term. On the other hand, looking at the outlook for the CYTK stock, short term indicators assign the stock an average of 50% Buy, while medium term indicators assign it an average of 50% Buy. Long term indicators on average place the stock in the category of 50% Buy.
Based on estimates by 12 analysts, where scores have ranged from 1.00 for a strong buy to 5.00 for a strong sell, 0 have rated the Cytokinetics Incorporated (CYTK) stock as a Hold, while 11 rate it as a Buy. 1 analyst(s) rate it as overweight while 0 of them rated it as underweight, whereas 0 suggest the stock as a Sell. The stock has an overall rating of Buy and investors could take advantage and scoop up stock of the company.
Looking further, we note the current price level is -15.38% off its SMA20 and -11.87% from its 50-day simple moving average. The RSI (14) is pointing at 35.38 while the volatility over the past week is 7.51% and jumps to 6.66% over the past one month. The beta value is 1.28, while the average true range (ATR) is currently pointing at 2.59. The average price target for the stock over the next 12 months is $55.83, with the estimates having a low of $46.00 and a high of $75.00. These price ends are -32.11% and -115.39% off the current price level respectively, although investors could be excited at the prospect of a -55.08% if the CYTK share price touches on the median price of $54.00.
Let’s briefly compare Cytokinetics Incorporated (CYTK) stock to its peers. We find that current price change of -2.74% and 76.93% over the past 12 months for CYTK competes that of Eiger BioPharmaceuticals Inc. (EIGR), which has seen its stock price fall -2.27% in the last trading session and was -58.16% over the last one year. Another of its peers Ligand Pharmaceuticals Incorporated (LGND) has dropped -4.45% previous session, and was 27.09% up over the past year, while Trevena Inc. (TRVN) was also up 3.75% in the last session, while its price remained in the red at -71.37% over the same period. In contrast to these companies, both the S&P 500 Index and the Dow Jones Industrial were at 0.92% and 0.51%, respectively, at close of the trading.
Coming back to Cytokinetics Incorporated (NASDAQ:CYTK), we note that the average 3-month trading volume was 902.55K. Current shares outstanding are 80.33 million.
The insiders hold 1.00% of the company’s shares. Investors should be excited about this stock as its upside potential is great, with current price pushing the stock -23.61% down in year-to-date price movement.